CN
CNSP.US CNS Pharmaceuticals Inc
- Market cap
- USD 4.22M
- P/E
- -
- P/B
- 0.29x
- ROE
- -82.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CNSP.US undervalued?
Graham numberThe Graham number of CNS Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CNS Pharmaceuticals Inc fundamental analysis
No fundamental analysis for CNS Pharmaceuticals Inc yet.
CNS Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemoth…
Full company profileCNS Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CNS Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -1.96K | -11.1K | -13.1K | -11.8K | -4.13K | -3.31K | - | - |
| Operating Income | -516K | -882K | -3.83M | -9.45M | -14.5M | -14.9M | -18.9M | -14.9M | -16.0M | -15.4M |
| EBITDA | -514K | -6.46M | -3.83M | -9.44M | -14.5M | -15.3M | -18.8M | -14.8M | -15.8M | -15.0M |
| Net Income | -526K | -7.39M | -3.92M | -9.46M | -14.5M | -15.3M | -18.9M | -14.9M | -15.9M | -15.1M |
| EPS | -29,248 | -410,661 | -217,749 | -525,437 | -499,834 | -339,425 | -149,613 | -466 | -36 | -2.20 |
| Balance Sheet | ||||||||||
| Total Assets | 162K | 683K | 7.91M | 15.9M | 8.76M | 13.1M | 1.70M | 8.70M | 8.62M | 21.9M |
| Total Liabilities | 221K | 1.23M | 311K | 1.91M | 2.14M | 4.92M | 6.13M | 2.52M | 4.10M | 3.74M |
| Shareholders' Equity | -58.5K | -549K | 7.60M | 13.9M | 6.62M | 8.13M | -4.43M | 6.18M | 4.52M | 18.2M |
| Cash & Short-term Investments | 111K | 283K | 7.24M | 14.0M | 5.00M | 10.1M | 549K | 6.46M | 7.20M | 20.0M |
| Total Debt | 122K | 317K | - | 439K | 388K | 410K | 301K | 326K | 329K | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -112K | -716K | -3.55M | -7.32M | -13.5M | -10.6M | -14.1M | -17.1M | -13.8M | -16.4M |
| Capital Expenditure | 3.00 | 5.00 | 20.1K | 17.9K | 5.75K | 4.42K | 3.90K | 4.19K | 18.2K | 20.0K |
| Free Cash Flow | -112K | -716K | -3.57M | -7.34M | -13.5M | -10.6M | -14.1M | -17.1M | -13.8M | -16.4M |
| Ratios | ||||||||||
| ROE | - | - | -51.6% | -67.8% | -218.9% | -187.8% | - | -240.5% | -350.5% | -82.7% |
| ROA | -324.6% | -1,081.7% | -49.5% | -59.7% | -165.5% | -117.0% | -1,108.3% | -170.8% | -183.8% | -68.6% |
| Debt to Equity | - | - | - | 0.03x | 0.06x | 0.05x | - | 0.05x | 0.07x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
CNS Pharmaceuticals Inc dividends
CNS Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Jul 22, 2025.
Who owns CNS Pharmaceuticals Inc
- Insiders 0.95%
- Institutions 21.16%
- Public & others 77.89%
- Shares outstanding 1.46M
- Free float 1.32M
Top funds holding CNSP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 8.26K | 0.57% | -0.21% | Sep 2026 |
| Fidelity Series Total Market Index | 555.00 | 0.04% | 0.00% | Sep 2026 |
Top institutions holding CNSP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Ikarian Capital, LLC | 136K | 9.29% | +196.38% | Jun 2026 |
| ADAR1 Capital Management LLC | 70.0K | 4.79% | 0.00% | Jun 2026 |
| Stonepine Capital Management Llc | 41.6K | 2.84% | -31.85% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 13.5K | 0.93% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 10.2K | 0.70% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.99K | 0.48% | 0.00% | Jun 2026 |
| UBS Group AG | 1.46K | 0.10% | +100.41% | Jun 2026 |
| Tower Research Capital LLC | 799.00 | 0.05% | -39.01% | Jun 2026 |
| Barclays PLC | 19.00 | 0.00% | 0.00% | Jun 2026 |
| BARRETT & COMPANY, INC. | 8.00 | 0.00% | 0.00% | Jun 2026 |
| Danske Bank A/S. | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Mccormack Advisors International | 0.00 | 0.00% | -100.00% | Jun 2026 |
CNS Pharmaceuticals Inc company profile
- Company name
- CNS Pharmaceuticals Inc
- Ticker
- CNSP.US
- Exchange
- USA Stocks
- Listed since
- Nov 8, 2019
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 8
- Fiscal year end
- December
- Address
- 2100 West Loop South, Houston, TX, United States, 77027
- Phone
- 800 946 9185
- Website
- cnspharma.com
About CNS Pharmaceuticals Inc
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
CNS Pharmaceuticals Inc management
5- Mr. Rami Levin M.B.A.President, CEO & Director · born 1969
- Mr. Steve O'Loughlin M.B.A.Chief Financial Officer · born 1985
- Mr. Eric Faulkner M.B.A., M.Sc.Chief Technology Officer · born 1973
- Mr. Dylan Wenke M.B.A.Chief Business Officer
- Dr. E. Lynne Kelley F.A.C.S., M.D.Chief Medical Officer · born 1963